In 1980, a startup in Thousand Oaks, California, set out to turn molecular biology into medicine. Forty-five years later, Amgen has fourteen products each generating more than $1 billion in annual revenue, posted $36.8 billion in 2025 sales, and serves 17 million patients worldwide. It did not invent the biotech industry. It proved the biotech industry could work.
Before Amgen, biotechnology was a laboratory curiosity. Genentech had demonstrated that recombinant DNA could produce human insulin. But producing a protein in a fermenter and building a pharmaceutical company around biologics were different propositions entirely. The former required science. The latter required manufacturing at scale, clinical development, regulatory strategy, and a sales force capable of convincing physicians to prescribe drugs made from living cells rather than chemical synthesis. Nobody had done all of that and survived as an independent company.
Amgen did. Its first commercial product, Epogen (epoetin alfa), was a recombinant erythropoietin that stimulated red blood cell production in dialysis patients. Before Epogen, chronic kidney disease patients depended on blood transfusions. The drug did not merely treat anaemia. It eliminated a dependency. Neupogen (filgrastim), which followed, reduced infection risk in chemotherapy patients by boosting white blood cell counts. These were not incremental improvements over existing medicines. They were proteins that the human body made naturally, manufactured at industrial scale and delivered as drugs.
By 2014, Amgen was generating $20.1 billion in revenue. That number alone tells you something about what happened between the startup years and the mature company: biologics had become the most valuable segment of the pharmaceutical industry, and Amgen had arrived there first. It had built the manufacturing infrastructure, the regulatory expertise, and the commercial engine that later entrants would spend decades trying to replicate.
In oncology, there is a protein called KRAS. It sits at the centre of cell growth signalling, and mutations in KRAS drive roughly a quarter of all human cancers. For forty years, KRAS was considered undruggable. Its surface was smooth, with no obvious pocket where a small molecule could bind and shut it down. Hundreds of research teams tried. The consensus in the field, repeated at conferences and in textbook chapters, was that KRAS could not be targeted directly.
Amgen’s scientists found a way. Sotorasib, marketed as LUMAKRAS, was approved in 2021 as the first drug to directly inhibit a KRAS mutation , specifically the G12C variant found in certain lung cancers. The mechanism was elegant: the molecule locked into a pocket on the mutant protein that only appeared when KRAS was in its inactive state, trapping it there. It was not brute force. It was structural biology at its most precise, exploiting a transient vulnerability that decades of research had missed.
The significance extended beyond the drug itself. LUMAKRAS proved that the “undruggable” designation was a failure of technology, not biology. Its approval in 2021 coincided with a year in which Amgen also gained approval for TEZSPIRE (tezepelumab), a first-in-class biologic for severe asthma developed with AstraZeneca. Two first-in-class mechanisms in a single year, from a company that was already four decades old. The 2021 revenue reached $26.0 billion.
By 2024, Amgen had fourteen products each generating more than $1 billion in annual revenue. That number requires context. Most pharmaceutical companies consider a single billion-dollar product a career-defining achievement. Amgen had fourteen running simultaneously, across four therapeutic pillars: oncology, cardiovascular, bone health, and inflammation.
Enbrel, the original TNF-blocker for autoimmune diseases, was the franchise that funded Amgen’s expansion beyond haematology. Repatha (evolocumab), a PCSK9 inhibitor, addressed cardiovascular risk with a mechanism entirely different from statins. Prolia and XGEVA (denosumab) became the standard of care in bone health , one for osteoporosis, the other for skeletal events in cancer. Otezla (apremilast), acquired from Celgene, gave Amgen an oral option in psoriasis. EVENITY (romosozumab) offered a bone-building mechanism for severe osteoporosis. Aimovig (erenumab) was the first CGRP inhibitor approved for migraine prevention. BLINCYTO (blinatumomab), a bispecific T-cell engager using Amgen’s proprietary BiTE technology, directed the immune system to attack leukaemia cells.
The revenue trajectory tells the story of compounding breadth. From $20.1 billion in 2014 to $23.7 billion in 2018 to $33.4 billion in 2024 , a 19 per cent jump in that final year alone, driven by 23 per cent volume growth. In 2024, Amgen invested a record $6.0 billion in research and development. The company was not harvesting its portfolio. It was still planting. By 2025, revenue reached $36.8 billion with 17 million patients served across four therapeutic pillars.
Amgen’s India patent portfolio reflects the company’s scientific output over two decades. Between 2003 and 2026, Amgen filed 406 patent applications with the Indian Patent Office. Of those, 31 have been granted. The grant rate is modest, but the filing volume signals sustained engagement with the Indian intellectual property system.
The filings span Amgen’s core technology platforms. BiTE (bispecific T-cell engager) antibody constructs, which underpin BLINCYTO and a pipeline of next-generation oncology candidates, represent a category of patents with particular relevance to India’s growing biologics sector. Amgen’s biosimilar business , it sells biosimilar versions of other companies’ biologics in some markets , adds another dimension: the same company that files originator patents also understands the biosimilar pathway from the inside.
For India, where biosimilar manufacturing is a strategic industry, Amgen’s patent estate creates a complex landscape. The 406 filings cover formulations, manufacturing processes, and novel molecular entities across oncology, immunology, and cardiovascular disease. Each granted patent establishes a boundary. Each application that was filed but not granted tells its own story about what India’s patent examiners considered novel and what they did not. The portfolio operates in approximately 100 countries globally, and the India filings represent one node in that network.
In 2023, Amgen completed its acquisition of Horizon Therapeutics for $27.8 billion. It was the largest deal in Amgen’s history and one of the largest biotech acquisitions ever. Horizon brought something Amgen did not have: a rare disease portfolio anchored by Tepezza (teprotumumab) for thyroid eye disease and Krystexxa (pegloticase) for chronic refractory gout.
The strategic logic was straightforward but the execution was not. The Federal Trade Commission challenged the acquisition, arguing that Amgen could use rebates on its existing portfolio to disadvantage Horizon’s competitors. Amgen prevailed, but the process demonstrated that antitrust scrutiny of pharmaceutical mergers had entered a new phase. The deal closed in October 2023. That year, Amgen’s revenue reached $28.2 billion , 7 per cent growth , with 27,000 employees.
The Horizon acquisition pushed Amgen into its fourth therapeutic pillar: rare disease, alongside the existing oncology, cardiovascular, and inflammation/immunology franchises. By 2024, the integration was reflected in the numbers. Revenue hit $33.4 billion, a 19 per cent increase. Sixteen of Amgen’s products posted record sales. The company that had once been a single-product biotech now operated across a breadth that rivalled diversified pharma companies ten times its age.
Sources: Amgen Annual Reports 2014–2025. Indian Patent Office (patent filing data). OPPI member directory.